Otsuka Pharmaceutical Co., Ltd.

208 articles about Otsuka Pharmaceutical Co., Ltd.

• Otsuka Pharma Licenses Pre-Phase 3 Topical Atopic Dermatitis Treatment To Medimetriks Pharmaceuticals, Inc.

  2/9/2016

• Ariad And Otsuka Pharma Submit New Drug Application In Japan For Ponatinib

  1/8/2016

• U.S. FDA Accepts First Digital Medicine New Drug Application For Otsuka Pharma And Proteus Digital Health, Inc.

  9/11/2015

• Efficacy Results Of Otsuka Pharma’s Delamanid (Deltyba) For Extensively Drug-Resistant Tuberculosis (XDR-TB) Published In The New England Journal of Medicine

  7/16/2015

• Otsuka Pharma, H. Lundbeck A/S Beat Competitors With FDA Approval of Schizophrenia Drug

  7/13/2015

• Otsuka Pharmaceutical Co., Ltd.’s JINARC The First-Ever Treatment Approved In Europe For Adults Living With ADPKD, A Chronic Genetic Kidney Disease

  5/27/2015

• Otsuka Pharmaceutical Co., Ltd. Release: Pre-Filled Dual-Chamber Syringe For Abilify Maintena (Aripiprazole) Prolonged-Release Suspension For Injection, Used In The Treatment Of Schizophrenia, Receives Positive CHMP Opinion (Approval In EU)

  3/30/2015

• Otsuka Pharmaceutical Co., Ltd. Release: First-Ever Treatment Approved In Canada For Adults Living With ADPKD, A Life-Threatening Kidney Disease

  3/2/2015

• Otsuka Pharmaceutical Co., Ltd. Release: First-Ever Treatment Approved In Canada For Adults Living With ADPKD, A Life-Threatening Kidney Disease

  2/27/2015

• Otsuka Pharmaceutical Co., Ltd. Release: CHMP Recommends Jinarc (Tolvaptan) For Approval In EU: The First Pharmaceutical Treatment For Autosomal Dominant Polycystic Kidney Disease (Adpkd)

  2/27/2015

• GW Pharmaceuticals And Otsuka Pharmaceutical Co., Ltd. Announce Results In First Of Three Sativex® Phase 3 Cancer Pain Trials

  1/8/2015

• Otsuka Pharmaceutical Co., Ltd. And H. Lundbeck A/S’s Brexpiprazole Demonstrates Statistically Significant Effects In New Phase 3 Studies In Adult Patients With Schizophrenia Presented At The American College Of Neuropsychopharmacology Annual Meeting

  12/11/2014

• Otsuka Pharmaceutical Co., Ltd. And H. Lundbeck A/S Present Phase 3 Data On Brexpiprazole As Adjunctive Therapy In Adult Patients With Major Depression At The American College Of Neuropsychopharmacology Annual Meeting

  12/10/2014

• Otsuka Pharmaceutical Co., Ltd. Release: U.S. FDA Approves The Labeling Update Of Abilify Maintena® (Aripiprazole) For Extended-Release Injectable Suspension To Describe New Clinical Data For The Treatment Of Acutely Relapsed Adults With Schizophrenia

  12/8/2014

• Otsuka Pharmaceutical Co., Ltd. Buys AVANIR Pharmaceuticals For $3.5 Billion

  12/2/2014

• Former VP, Oncology, From Pfizer And Otsuka Pharmaceutical Co., Ltd. Joins Accelovance To Augment Oncology Growth

  9/30/2014

• U.S. FDA Accepts Otsuka Pharmaceutical Co., Ltd. And Lundbeck Inc.'s Filing For Review Of Brexpiprazole For The Treatment Of Schizophrenia And As Adjunctive Therapy For The Treatment Of Major Depression

  9/24/2014

• NuView Life Sciences Inc. Enters Global Licensing Agreement With Otsuka Pharmaceutical Co., Ltd.

  9/17/2014

• Otsuka Pharmaceutical Co., Ltd. And H. Lundbeck A/S Submit New Drug Application In The US For Brexpiprazole For The Treatment Of Schizophrenia And As Adjunctive Therapy For The Treatment Of Major Depressive Disorder

  7/14/2014

• Otsuka Pharmaceutical Co., Ltd. Release: New Once-Monthly Treatment For Schizophrenia, ABILIFY MAINTENA™ (Aripiprazole For Prolonged Release Injectable Suspension), Now Available In Canada

  5/5/2014